openPR Logo
Press release

RNA Therapeutics 2020 to Highlight Downregulating Therapeutic Technologies

11-08-2019 03:35 PM CET | Health & Medicine

Press release from: SMI

RNA Therapeutics 2020

RNA Therapeutics 2020

SMi Reports: The morning session on day two of SMi’s RNA Therapeutics conference will pay a particular focus to “Downregulating Therapeutic Technologies”.

SMi are proud to host the 11th annual RNA Therapeutics conference on February 19th – 20th 2020 in London. This year’s event will maintain a focus on the latest research and developments on delivery system technologies aimed at tackling difficult targets within the human body.

An early bird savings of £200 expires on 29th November. Interested parties are encouraged to register early at www.therapeutics-rna.com/openpr4

The conference will pay close attention to regulations within the field of RNA Therapeutics, such as, continuing upon patenting novel products, the release of new 2020 regulations in the clinical trials arena and ensuring compliance. The agenda for the morning of day two will highlight “Downregulating Therapeutic Technologies”.

Session Highlights Include:

MiRNA Therapeutics: From Discovery to the Bedside

• The non-coding genome makes up 98.8% of the human genome. Most of this non-coding genome is transcribed into non-coding RNAs that may play an important role in cellular regulation in health and disease; these non-coding RNAs could be novel targets for future medicines.
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
• The presentation will summarise the opportunities and challenges of developing microRNA-based drugs and will illustrate the successful generation of an anti-fibrotic microRNAbased therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome.
Ekkehard Leberer, Senior Director, Alliance Management, Sanofi

MicroRNA Replacement Therapy: Myth or Reality?

• miRNAs - Mother Nature has already done most of the job! ...
• miRNAs as novel therapeutic intervention in Oncology
• miRNA replacement therapy (miRNA mimics)
Michel Janicot, Chief Development Officer, InteRNA Technologies

NanoGenics; Using a peptide nanoparticle, LipTide, to develop a siRNA product portfolio
• How does the peptide nanoparticle, LipTide resemble an artificial virus?
• Delivering siRNA with LipTide across multiple administration routes
• Case study; Targeting the MRTF pathway to develop siRNA anti-fibrotic drugs

Simon Newman, CSO, Nanogenics

This year’s agenda also includes a Focus Day held the 18th of February including sessions on recent developments in “Oligonucleotide Delivery Systems”.

View the full event programme at www.therapeutics-rna.com/openpr4

RNA Therapeutics
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
ChemGenes | Thermo Fisher Scientific

--- ENDS –
Contact Information:
For media enquiries contact Alia Malick on +44 (0)20 7827 6168
For all delegate enquiries, contact Hakam Panum on +44 (0)20 7827 6128

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNA Therapeutics 2020 to Highlight Downregulating Therapeutic Technologies here

News-ID: 1864104 • Views: 324

More Releases from SMI

Senior US officials from fuel policy teams and combat wings to present at Milita …
SMi reports: Senior US officials will be presenting at the 21st Annual Military Airlift Air-to-Air Refuelling conference in Seville, this December Air-to-air refuelling remains a key mission multiplier, utilised extensively in Operation Inherent Resolve to extend flight times for bombing runs against ISIS. As the US Air Force explores the greater utilisation of commercial refuellers for CONUS operations to free military assets for combat and international deployment there is a critical
Senior experts to discuss Naval Mine Countermeasures at Unmanned Maritime System …
The challenge posed by potential adversary mining capabilities is real and growing. For all navies, there is only one way to completely “Take the sailor out of the minefield,” and that is to leverage unmanned technologies to hunt and destroy mines from a distance.* By embracing technological advancements in unmanned systems, such as UUVs and USVs, they could sweep large portions of the sea while minimizing the risk to sailors. For
Military Robotics and Autonomous Systems 2020 announced as a Virtual Event
SMi Reports: Due to the ongoing challenges surrounding COVID-19, Military Robotics and Autonomous Systems in September will now run as a virtual event. With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the 3rd annual Military Robotics and Autonomous Systems Conference on the 2nd-3rd September 2020 into a fully interactive virtual meeting. All attendance by military and government will be free of charge
04-07-2020 | Health & Medicine
SMI
Associates of Cape Cod Webinar on Recombinant Chromogenic Assay as Alternate Met …
SMi Reports: Associates of Cape Cod to host an online webinar taking place on Wednesday 29th April 2020. SMi Group is delighted to announce a free webinar led by Associates of Cape Cods on 'Recombinant Chromogenic Assay as Alternate Methods for Bacterial Endotoxins Test (BET)' taking place on 29th April 2020 at 10am EDT (3pm BST - UK time). The webinar will aim to review the global perspective on the use

All 5 Releases


More Releases for RNA

RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led